Ibogaine Treatment Guide: Wisconsin (2026 Update)

Drug Addiction Situation in Wisconsin

As of May 2026, Wisconsin’s addiction landscape is marked by a dangerous rise in polysubstance use. While total overdose deaths have seen a promising one-third decrease since the peaks of 2023, the toxicity of the supply remains high.

• Fentanyl and Stimulants: Fentanyl is involved in approximately 69% of all overdose deaths in the state. However, the “new surge” involves opioids mixed with stimulants. In the Northern and Western regions of Wisconsin, methamphetamine is the primary co-contaminant, while in Southeastern Wisconsin (including Milwaukee), cocaine is nearly 10 times more likely to be found in combination with opioids.

• The Methamphetamine Surge: Wisconsin has seen a significant resurgence of high-potency methamphetamine, largely produced in Mexico and transported into the state. This has led to increased brain-circuit damage related to reward and stress, making traditional cessation methods nearly impossible for many.

  +1

   

Mental Health Situation in Wisconsin

Wisconsin is currently grappling with a severe mental health workforce crisis that is failing to keep pace with demand.

• Workforce Shortage: According to the 2026 Wisconsin Health Care Workforce Report, hospitals are seeing a vacancy rate for physicians exceeding 15%. Administrative and payer burdens are pulling remaining providers away from patient care.

   

• Bottlenecks and Boarding: Hundreds of patients are “stuck” in Wisconsin hospitals daily because the state lacks proper post-acute and community-based mental health settings for discharge.

   

• Worker Burnout: In April 2026, mental health workers at major facilities like Rogers Behavioral Health voted overwhelmingly to unionize, citing chronic understaffing and unmanageable workloads as primary drivers of the crisis.

   

Ineffective Treatments for Addiction and Mental Health in Wisconsin

The “revolving door” of traditional rehab is leaving many Wisconsinites behind. Because standard models often fail to repair the neurological damage of synthetic drugs, it is highly recommended that treatment-resistant patients explore neuro-regenerative options.

• Abstinence Model Failures: Standard 30-day programs in Wisconsin often focus on behavioral changes but do not address the depletion of dopamine caused by long-term meth and fentanyl use.

• MAT Bottlenecks: While there are 29 Opioid Treatment Programs in Wisconsin serving over 12,000 patients, many individuals find themselves tethered to life-long maintenance medications rather than achieving true neurological recovery.

• Waitlists: Due to the 15% physician vacancy rate, patients seeking specialized trauma or depression therapy often face months-long waitlists, allowing their conditions to worsen.

How right to try Policy is Impacting Ibogaine in Wisconsin

The path for ibogaine access fundamentally changed on April 18, 2026, with a landmark federal Executive Order focused on “Accelerating Medical Treatments for Serious Mental Illness.”

• Federal Mandate: This order directs the FDA and DEA to facilitate “Right to Try” pathways for ibogaine compounds, recognizing their potential to reverse the crisis for patients who have failed standard therapies.

• State Impact: The order allocates $50 million through ARPA-H to support state governments that develop programs for breakthrough psychedelic therapies. For Wisconsin, this federal signal provides the legal and financial framework to move toward medicalization for those who have exhausted all other options.

   

Legal Status of Ibogaine in Wisconsin

Despite the federal momentum, ibogaine remains a Schedule I controlled substance under Wisconsin law. However, the state’s legislative environment is shifting:

• Psilocybin Research (AB 753): In the 2025-2026 session, Wisconsin introduced Assembly Bill 753, which aims to create a medicinal psilocybin treatment fund and a pilot program at UW-Madison.

• The Legal Precedent: While specifically targeting psilocybin for PTSD, this bill sets the stage for Wisconsin to adopt broader psychedelic-assisted therapies, including ibogaine, as federal FDA clinical study clearances (like the April 2026 clearance of DemeRx NB) continue to move forward.

Research of Ibogaine in Wisconsin

Wisconsin is a major player in psychiatric research, particularly through the University of Wisconsin-Madison.

• Clinical Trials: Under the proposed AB 753, UW-Madison is being positioned as a hub for studying the effects of plant-based medicines on PTSD and treatment-resistant addiction.

• FDA Activity: In late April 2026, the FDA allowed the first-ever U.S. clinical study of an ibogaine derivative to proceed. Wisconsin researchers are closely monitoring this data to integrate “rapid detox” protocols into the state’s future behavioral health infrastructure.

Travel Logistics to Playa Del Carmen (Ibogaine by David Dardashti)

Since local access in Wisconsin is currently limited to high-barrier research studies, many residents travel to the medical facility in Mexico for immediate, supervised care.

• Departure Airports: Most residents fly out of Milwaukee Mitchell International (MKE), Dane County Regional (MSN), or Green Bay (GRB).

• The Concierge Experience: David Dardashti’s team manages all round-trip airfare and itineraries once medical intake is cleared, booking flights directly to Cancun (CUN).

• Safe Arrival: Upon landing in Cancun, a private, secure driver vetted by the clinic meets you at the arrivals terminal.

• Final Leg: You are transported in a comfortable, air-conditioned vehicle directly to the facility in Playa Del Carmen. This 45-minute drive south of the airport allows you to decompress and transition into a safe, medically supervised environment before your treatment begins.